Kura Oncology (KURA) to Release Quarterly Earnings on Thursday

Kura Oncology (NASDAQ:KURA) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Kura Oncology to post earnings of ($0.56) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. During the same period last year, the company earned ($0.49) earnings per share. On average, analysts expect Kura Oncology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Kura Oncology Trading Down 0.7 %

Shares of NASDAQ:KURA traded down $0.14 during trading on Tuesday, hitting $19.92. 177,618 shares of the company were exchanged, compared to its average volume of 1,303,985. The firm’s 50 day moving average price is $20.64 and its 200-day moving average price is $15.71. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 0.02.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Monday, April 22nd. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. JMP Securities boosted their price target on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research report on Wednesday, January 31st. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.28.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.